PID
MCID: PLV003
MIFTS: 55

Pelvic Inflammatory Disease (PID)

Categories: Nephrological diseases, Reproductive diseases

Aliases & Classifications for Pelvic Inflammatory Disease

MalaCards integrated aliases for Pelvic Inflammatory Disease:

Name: Pelvic Inflammatory Disease 12 74 54 42 3 43 15 17 71
Pid 12 3

Classifications:



External Ids:

Disease Ontology 12 DOID:1003
MeSH 43 D000292
NCIt 49 C3889
SNOMED-CT 67 37518008
ICD10 32 N70-N77 N73.9
UMLS 71 C0242172

Summaries for Pelvic Inflammatory Disease

MedlinePlus : 42 Pelvic inflammatory disease (PID) is an infection and inflammation of the uterus, ovaries, and other female reproductive organs. It causes scarring in these organs. This can lead to infertility, ectopic pregnancy, pelvic pain, abscesses, and other serious problems. PID is the most common preventable cause of infertility in the United States. Gonorrhea and chlamydia, two sexually transmitted diseases, are the most common causes of PID. Other bacteria can also cause it. You are at greater risk if you Are sexually active and younger than 25 Have more than one sex partner Douche Some women have no symptoms. Others have pain in the lower abdomen, fever, smelly vaginal discharge, irregular bleeding, and pain during intercourse or urination. Doctors diagnose PID with a physical exam, lab tests, and imaging tests. Antibiotics can cure PID. Early treatment is important. Waiting too long increases the risk of infertility.

MalaCards based summary : Pelvic Inflammatory Disease, also known as pid, is related to endometritis and salpingitis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Pelvic Inflammatory Disease is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Aztreonam and Norgestimate have been mentioned in the context of this disorder. Affiliated tissues include testes, uterus and ovary, and related phenotypes are Reduced mammosphere formation and immune system

Disease Ontology : 12 A female reproductive system disease that is characterized by an infection of the female reproductive organs.

CDC : 3 Untreated sexually transmitted diseases (STDs) can cause pelvic inflammatory disease (PID), a serious condition, in women. 1 in 8 women with a history of PID experience difficulties getting pregnant. You can prevent PID if you know how to protect yourself.

Wikipedia : 74 Pelvic inflammatory disease, also known as pelvic inflammatory disorder (PID), is an infection of the... more...

Related Diseases for Pelvic Inflammatory Disease

Diseases related to Pelvic Inflammatory Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 512, show less)
# Related Disease Score Top Affiliating Genes
1 endometritis 33.1 TLR4 TLR2 HLA-DQA1
2 salpingitis 32.9 TLR2 HSPD1 CRP CD40LG
3 peritonitis 32.9 TLR4 TLR2 IFNG CRP CCL2
4 chlamydia 32.5 TLR4 TLR2 IFNG HSPD1 CRP CD40LG
5 cervicitis 31.2 TLR4 TLR2 IL2 HSPD1
6 appendicitis 31.0 TLR4 MMP9 IL2 IFNG CRP CCL2
7 agammaglobulinemia, x-linked 30.8 IL2 CXCL12 CD40LG
8 common variable immunodeficiency 30.8 TLR2 IL2 IFNG CD40LG
9 exanthem 30.8 IL2 CRP CD40LG
10 diarrhea 30.7 TLR4 IL2 IFNG CD40LG
11 urethritis 30.6 TLR4 TLR2 HSPD1 CRP CD40LG
12 ileus 30.5 IFNG CRP CCL2
13 immune deficiency disease 30.5 IL2 IL13 IFNG CXCL12 CD40LG CCL2
14 secondary progressive multiple sclerosis 30.5 MMP9 IFNG CD40LG CCL2
15 miliary tuberculosis 30.5 IFNG CRP CD40LG
16 anogenital venereal wart 30.5 TLR6 TLR4 TLR2 TLR1 IL2
17 salmonellosis 30.4 TLR6 TLR4 TLR2 TLR1 IFNG
18 strongyloidiasis 30.4 IL13 IFNG CD40LG
19 dysentery 30.4 TLR4 TLR2 CRP CD40LG
20 candidiasis 30.4 TLR4 TLR2 IL2 IFNG CD40LG
21 familial mediterranean fever 30.4 TLR4 TLR2 CRP
22 cystitis 30.3 TLR4 IL2 CRP CDH1 CCL2
23 histoplasmosis 30.3 IFNG HLA-DQA1 CD40LG
24 acquired immunodeficiency syndrome 30.2 IL2 IFNG CRP CD40LG
25 adenomyosis 30.2 MMP9 MMP2 CDH1
26 vulvovaginal candidiasis 30.2 TLR2 LCN2 IL2 IFNG
27 gastroenteritis 30.2 MMP9 IFNG CRP CDH1
28 toxic shock syndrome 30.2 TLR4 TLR2 IL2 IFNG HSPD1 CRP
29 acute cystitis 30.2 TLR4 TLR2 LCN2 CRP CD40LG CCL2
30 extrapulmonary tuberculosis 30.2 TLR2 TIRAP IFNG CRP CCL2
31 myocarditis 30.1 TLR4 IL2 IFNG CD40LG CCL2
32 keratoconjunctivitis 30.1 MMP9 IL2 IL13 IFNG CCL2
33 conjunctivitis 30.1 MMP9 IL2 IL13 IFNG CCL2
34 pyelonephritis 30.1 TLR4 LCN2 IFNG CRP CCL2
35 cervical cancer 30.0 TLR4 MMP9 MMP2 IL2 IFNG CDH1
36 inclusion conjunctivitis 30.0 HSPD1 CD40LG
37 lung disease 29.9 TLR4 TLR2 MMP9 IL13 IFNG CRP
38 skin disease 29.8 TLR4 TLR2 IL2 IL13 IFNG CRP
39 body mass index quantitative trait locus 11 29.7 TLR6 TLR4 TLR2 TLR1 LCN2 CRP
40 proteasome-associated autoinflammatory syndrome 1 29.6 TLR6 TLR4 TLR2 MMP9 IL13 IFNG
41 chlamydia pneumonia 29.6 TLR6 TLR4 TLR2 TLR1 HSPD1 CRP
42 bacterial infectious disease 29.5 TLR4 TLR2 TLR1 LCN2 IFNG HSPD1
43 autoimmune disease 29.5 MMP9 IL2 IL13 IFNG HSPD1 HLA-DQA1
44 meningitis 29.4 TLR4 TLR2 MMP9 IL2 IFNG CXCL12
45 myocardial infarction 29.4 TLR4 TLR2 MMP9 MMP2 LCN2 IFNG
46 myeloma, multiple 29.2 TLR4 MMP9 MMP2 IL2 IFNG CXCL12
47 ovarian cancer 29.1 TLR4 MMP9 MMP2 LCN2 IL2 IFNG
48 pneumonia 28.8 TLR6 TLR4 TLR2 MMP9 IL2 IL13
49 colorectal cancer 28.6 TLR6 TLR4 TLR2 TLR1 MMP9 MMP2
50 fitz-hugh-curtis syndrome 11.8
51 pick disease of brain 11.2
52 benign multicystic peritoneal mesothelioma 11.2
53 heart valve disease 11.2
54 ectopic pregnancy 10.8
55 infertility 10.8
56 bacterial vaginosis 10.6
57 fungal keratitis 10.6 TLR4 TLR2 MMP9
58 prosthetic joint infection 10.6 TLR4 TLR2 CRP
59 neurosyphilis 10.6 TLR6 TLR2 TLR1
60 autoimmune myocarditis 10.6 IFNG CCL2
61 orbital plasma cell granuloma 10.6 CRP CD40LG
62 tuberculous meningitis 10.6 TLR2 MMP9 CCL2
63 aztreonam allergy 10.6 IL2 IL13
64 plague 10.6 TLR6 TLR4 TLR2
65 chronic meningitis 10.6 MMP9 CRP CD40LG
66 systemic autoimmune disease 10.6 MMP9 CRP
67 extracranial arteriovenous malformation 10.6 MMP9 MMP2
68 blood group, globoside system 10.6 TLR4 TLR2 CRP
69 toxic pneumonitis 10.6 TLR6 TLR4
70 pneumonic plague 10.6 TLR4 TLR2 IL2
71 focal myositis 10.6 MMP9 MMP2
72 rosacea 10.6 TLR2 MMP9 CRP
73 fixed drug eruption 10.6 IL2 IFNG
74 acute pericementitis 10.6 TLR6 TLR2
75 epididymis disease 10.6 TLR4 CRP CD40LG
76 amebiasis 10.6 TLR4 TLR2 CD40LG
77 neuroretinitis 10.6 IFNG CRP CD40LG
78 legionnaire disease 10.6 TLR2 CRP CD40LG
79 sebaceous gland disease 10.6 TLR4 TLR2 CRP
80 chronic orbital inflammation 10.6 CRP CD40LG
81 gastrointestinal tuberculosis 10.6 IFNG CRP CD40LG
82 scleral disease 10.6 IL2 CRP CD40LG
83 abdominal tuberculosis 10.6 IFNG CRP CD40LG
84 uremic pruritus 10.6 IL2 CRP
85 bronchopneumonia 10.6 TLR4 CRP CD40LG
86 lung abscess 10.6 IFNG CRP CD40LG
87 ocular toxoplasmosis 10.6 TLR1 CD40LG
88 acute proliferative glomerulonephritis 10.6 CRP CD40LG CCL2
89 lentigo maligna melanoma 10.5 MMP9 MMP2
90 orchitis 10.5 IL2 CRP CD40LG
91 penile disease 10.5 TLR4 TLR2 IL2
92 boutonneuse fever 10.5 TLR4 IL2 CD40LG
93 central nervous system vasculitis 10.5 IFNG CRP CD40LG
94 erysipelas 10.5 IL2 CRP CD40LG
95 filarial elephantiasis 10.5 TLR4 TLR2 IL13
96 periapical granuloma 10.5 TLR2 IL2 CCL2
97 infective endocarditis 10.5 TLR6 TLR2 CRP
98 keratitis, hereditary 10.5 TLR4 TLR2 MMP9
99 endometriosis 10.5
100 acute transverse myelitis 10.5 MMP9 MMP2
101 angiostrongyliasis 10.5 MMP9 IL2 IL13
102 chorioretinitis 10.5 IL2 IFNG CD40LG
103 spondyloarthropathy 10.5 IL2 IFNG CCL2
104 lymphoid interstitial pneumonia 10.5 IL2 CRP CD40LG
105 pericardial tuberculosis 10.5 IFNG CRP
106 combat disorder 10.5 TLR6 TLR4 TLR2 TLR1
107 gingival disease 10.5 TLR4 TLR2 MMP9 CRP
108 skeletal tuberculosis 10.5 IFNG CRP
109 bacterial sepsis 10.5 TLR4 TLR2 TLR1 CRP
110 pyuria 10.5 LCN2 CRP CD40LG
111 lichen disease 10.5 IL2 IFNG CD40LG
112 periapical periodontitis 10.5 TLR2 MMP9 MMP2
113 endometrial disease 10.5 TLR6 TLR4 TLR2 TLR1
114 suppurative otitis media 10.5 TLR4 TLR2 CRP CD40LG
115 pleural tuberculosis 10.5 IL2 IFNG CCL2
116 fallopian tube disease 10.5 TLR4 TLR2 CRP CD40LG
117 acute salpingo-oophoritis 10.5 LCN2 CHI3L1
118 african tick-bite fever 10.5 IL13 IFNG CD40LG
119 common cold 10.5 TLR4 TLR2 IL13
120 loeffler syndrome 10.5 IL13 CD40LG
121 respiratory allergy 10.5 TLR4 TLR2 IL13
122 middle ear disease 10.5 TLR4 TLR2 CRP CD40LG
123 obstructive jaundice 10.5 TLR4 IL2 CRP
124 stevens-johnson syndrome/toxic epidermal necrolysis 10.5 IL2 IL13 IFNG
125 anuria 10.5 LCN2 CRP CD40LG
126 cellulitis 10.5 CRP CHI3L1 CD40LG
127 plasmodium vivax malaria 10.5 IL2 IFNG CD40LG
128 aggressive periodontitis 10.5 TLR4 TLR2 MMP9 CCL2
129 carotid artery disease 10.5 MMP9 CRP CCL2
130 autoimmune disease of endocrine system 10.5 IL2 IFNG CD40LG
131 pericarditis 10.5 IFNG CRP CD40LG
132 nasal cavity squamous cell carcinoma 10.5 MMP9 MMP2
133 lipoid nephrosis 10.5 IL13 CD40LG CCL2
134 bacterial pneumonia 10.5 TLR4 TLR2 CRP CD40LG
135 vaginal discharge 10.5
136 tropical spastic paraparesis 10.5 MMP9 IL2 IFNG
137 melioidosis 10.5 TLR4 TLR2 TLR1 IFNG
138 ischemic colitis 10.5 MMP9 MMP2 CRP
139 danubian endemic familial nephropathy 10.5 LCN2 CRP CD40LG
140 clonorchiasis 10.5 IL2 IFNG CTSB
141 hand, foot and mouth disease 10.5 TLR4 IL13 IFNG
142 autoimmune uveitis 10.5 IL2 IFNG CCL2
143 cystic echinococcosis 10.5 TLR4 TLR2 IFNG CD40LG
144 echinococcosis 10.5 TLR4 TLR2 IFNG CD40LG
145 alcoholic hepatitis 10.5 TLR4 TLR2 CRP CCL2
146 yellow fever 10.5 CRP CD40LG CCL2
147 nonspecific interstitial pneumonia 10.5 IL13 IFNG CCL2
148 chorioamnionitis 10.5 TLR4 MMP9 CRP CCL2
149 tuberculous peritonitis 10.5 IFNG CRP
150 acute salpingitis 10.5
151 scleritis 10.5 MMP9 IFNG CRP CCL2
152 granulomatosis with polyangiitis 10.5 TLR4 TLR2 CRP CD40LG
153 atopic keratoconjunctivitis 10.5 IL2 IFNG
154 retinal vein occlusion 10.5 CXCL12 CD40LG CCL2
155 coronary stenosis 10.5 TLR4 CXCL12 CRP
156 posterior uveitis 10.5 IL2 IL13 IFNG
157 polyradiculoneuropathy 10.5 IFNG CXCL12 CD40LG
158 parenchymatous neurosyphilis 10.5 TLR6 TLR1
159 aphthous stomatitis 10.5 TLR4 TLR2 IL2 IFNG
160 systolic heart failure 10.4 MMP9 MMP2 CRP
161 allergic conjunctivitis 10.4 IL2 IL13 IFNG
162 crohn's colitis 10.4 IL2 IFNG CDH1
163 typhoid fever 10.4 TLR4 IFNG CRP CD40LG
164 pulmonary sarcoidosis 10.4 IL2 IFNG CCL2
165 osteomyelitis 10.4 TLR4 TLR2 IFNG CCL2
166 spastic entropion 10.4 MMP9 MMP2
167 lymphadenitis 10.4 TLR4 IFNG CRP
168 viral meningitis 10.4 IFNG CRP CD40LG CCL2
169 spondylitis 10.4 IFNG CRP CHI3L1
170 hepatitis a 10.4 TLR4 IL2 IFNG
171 chickenpox 10.4 IL2 IFNG CRP CD40LG
172 neuritis 10.4 MMP9 IFNG CCL2
173 eosinophilic meningitis 10.4 MMP9 IL2 IL13 CD40LG
174 relapsing polychondritis 10.4 IL2 IFNG CRP CCL2
175 cerebral aneurysms 10.4 MMP2 CTSB CCL2
176 temporal arteritis 10.4 IFNG CRP CD40LG CCL2
177 dengue hemorrhagic fever 10.4 IL13 IFNG CD40LG
178 cholangitis 10.4 TLR4 IL2 CRP CD40LG
179 vogt-koyanagi-harada disease 10.4 TLR2 IFNG HLA-DQA1
180 collagen disease 10.4 IL13 CRP CD40LG
181 brain edema 10.4 MMP9 IL2 IFNG CRP
182 mumps 10.4 IL2 IFNG CD40LG
183 norwegian scabies 10.4 IL13 CD40LG
184 lymphatic system disease 10.4 IL2 IFNG CRP CD40LG
185 blood coagulation disease 10.4 IL2 CRP CD40LG
186 microvascular complications of diabetes 1 10.4 MMP9 CXCL12 CCL2
187 listeriosis 10.4 TLR4 TLR2 IL2 CDH1
188 lung giant cell carcinoma 10.4 MMP9 MMP2 CDH1
189 light chain deposition disease 10.4 MMP9 MMP2
190 paranasal sinus disease 10.4 IL13 IFNG CRP CD40LG
191 food allergy 10.4 TLR4 TLR2 IL13 IFNG
192 parotitis 10.4 MMP9 MMP2 CRP CD40LG
193 perinatal necrotizing enterocolitis 10.4 TLR6 TLR4 TLR2 TLR1 CRP
194 pyosalpinx 10.4
195 anus disease 10.4 TLR4 TLR2 TLR1 IL2 CRP
196 onchocerciasis 10.4 IL2 IL13 HLA-DQA1
197 oral submucous fibrosis 10.4 MMP9 MMP2 CDH1
198 superficial basal cell carcinoma 10.4 TLR6 TLR4 TLR2 TLR1 IL2
199 allergic asthma 10.4 TLR4 TLR2 IL13 IFNG
200 cat-scratch disease 10.4 HSPD1 CRP CD40LG
201 aortic aneurysm, familial abdominal, 1 10.4 MMP9 MMP2 CRP CCL2
202 myd88 deficiency 10.4 TLR6 TLR4 TLR2 TLR1 TIRAP
203 irak4 deficiency 10.4 TLR6 TLR4 TLR2 TLR1 TIRAP
204 cervical adenitis 10.4 HSPD1 CRP CD40LG
205 bartonellosis 10.4 HSPD1 CRP CD40LG
206 invasive aspergillosis 10.4 TLR6 TLR4 TLR2 TLR1 IFNG
207 aspergillosis 10.4 TLR6 TLR4 TLR2 TLR1 IFNG
208 pulmonary fibrosis 10.4 MMP9 MMP2 IL13 CCL2
209 sclerosing cholangitis 10.4 TLR4 IL2 CD40LG
210 chronic fatigue syndrome 10.4 TLR4 IL2 IL13 IFNG
211 coronary artery anomaly 10.4 MMP9 CRP CD40LG CCL2
212 tonsillitis 10.4 TLR4 TLR2 TLR1 IL2 IFNG
213 mouth disease 10.4 TLR4 IL13 IFNG CRP
214 gastric cardia carcinoma 10.4 CTSB CDH1
215 oral cancer 10.4 MMP9 MMP2 CDH1
216 diphtheria 10.4 IL2 IL13 IFNG CD40LG
217 acute female pelvic peritonitis 10.4
218 herpes zoster 10.4 TLR2 IL2 IFNG CRP CD40LG
219 paracoccidioidomycosis 10.4 TLR4 TLR2 IL2 IFNG CD40LG
220 gingivitis 10.3 TLR2 MMP9 IL2 IFNG CCL2
221 stomatitis 10.3 TLR4 TLR2 IL2 IFNG CD40LG
222 contact dermatitis 10.3 TLR4 TLR2 IL2 IFNG CCL2
223 ureteral disease 10.3 LCN2 CRP CDH1 CCL2
224 brucellosis 10.3 TLR4 IL2 IFNG CRP CD40LG
225 mycoplasma pneumoniae pneumonia 10.3 TLR2 IL13 IFNG CRP CD40LG
226 retinal detachment 10.3 MMP9 MMP2 IFNG CCL2
227 limb ischemia 10.3 MMP9 MMP2 CXCL12 CCL2
228 pyelitis 10.3 TLR4 TLR2 LCN2 CRP CD40LG
229 bronchiolitis obliterans 10.3 TLR4 MMP9 IL13 IFNG CRP
230 urinary tract obstruction 10.3 LCN2 CRP CDH1 CCL2
231 severe acute respiratory syndrome 10.3 IL2 IFNG CRP CD40LG CCL2
232 cerebrovascular disease 10.3 TLR4 MMP9 CRP CHI3L1 CD40LG
233 uveal disease 10.3 IL2 IFNG CRP CD40LG CCL2
234 preterm premature rupture of the membranes 10.3 TLR4 TLR2 MMP9 MMP2 CRP
235 colitis 10.3 TLR4 TLR2 IL2 IL13 IFNG
236 nasal cavity disease 10.3 TLR4 TLR2 IL2 IL13 IFNG
237 hashimoto thyroiditis 10.3 IL2 IFNG HLA-DQA1 CRP
238 demyelinating disease 10.3 MMP9 IL2 IFNG CD40LG CCL2
239 oral cavity cancer 10.3 TLR6 TLR2 MMP9 CDH1 CD40LG
240 varicose veins 10.3 MMP9 MMP2 CCL2
241 tularemia 10.3 TLR4 TLR2 HSPD1 CD40LG
242 streptococcus pneumonia 10.3 TLR6 TLR4 TLR2 TLR1 CRP CD40LG
243 endocardium disease 10.3 TLR2 HSPD1 CRP CD40LG
244 tongue disease 10.3 MMP9 MMP2 CDH1
245 fibromyalgia 10.3 IL2 CRP CCL2
246 allergic hypersensitivity disease 10.3 TLR4 TLR2 IL2 IL13 IFNG
247 renal fibrosis 10.3 MMP9 MMP2 CDH1 CCL2
248 corneal disease 10.3 TLR4 TLR2 MMP9
249 septic arthritis 10.3 TLR4 TLR2 MMP2 IFNG CRP
250 japanese spotted fever 10.3 HSPD1 CRP CD40LG CCL2
251 vaginal disease 10.3 TLR6 TLR4 TLR2 TLR1 IL2 CRP
252 alopecia areata 10.3 IL2 IL13 IFNG HLA-DQA1
253 legionellosis 10.3 TLR4 TLR2 HSPD1 CD40LG
254 tetanus 10.3 IL2 IL13 IFNG CRP CD40LG
255 plasmodium falciparum malaria 10.3 IFNG CRP CD40LG
256 herpangina 10.3 TLR6 TLR4 TLR2 TLR1 IL2 CD40LG
257 otitis media 10.3 TLR4 TLR2 TLR1 IFNG CRP CD40LG
258 takayasu arteritis 10.3 MMP9 MMP2 IL2 CRP CD40LG
259 ulcerative colitis 10.3 TLR4 IL2 IL13 IFNG CRP
260 schistosomiasis 10.3 IL2 IL13 IFNG CD40LG CCL2
261 rheumatic fever 10.3 TLR2 IL2 IFNG HLA-DQA1 CD40LG
262 bacterial meningitis 10.3 TLR4 TLR2 MMP9 IFNG CRP CCL2
263 acute disseminated encephalomyelitis 10.3 HSPD1 HLA-DQA1 CD40LG
264 q fever 10.3 TLR4 TLR2 TLR1 IFNG CD40LG CCL2
265 chronic pain 10.3
266 spondyloarthropathy 1 10.3 TLR4 HSPD1 CRP CD40LG
267 bronchitis 10.3 TLR4 TLR2 MMP9 IL13 CRP CD40LG
268 lepromatous leprosy 10.3 TLR2 IL2 IFNG HSPD1
269 autoimmune disease of gastrointestinal tract 10.3 TLR4 IL2 IFNG HLA-DQA1 CD40LG
270 hypersensitivity reaction type iv disease 10.2 TLR4 TLR2 IL2 IFNG CRP CD40LG
271 rubella 10.2 TLR4 IL2 IFNG HLA-DQA1 CD40LG
272 intracranial berry aneurysm 10.2 TLR4 MMP9 CRP
273 pleurisy 10.2 TLR4 TLR2 IL2 IFNG CRP CCL2
274 syphilis 10.2
275 juvenile rheumatoid arthritis 10.2 IL2 IFNG HLA-DQA1 CRP CCL2
276 pulmonary tuberculosis 10.2 TLR4 TLR2 IL2 IFNG CRP CCL2
277 conjunctival disease 10.2 TLR4 TLR2 IL2 IL13 CRP CD40LG
278 pulmonary disease, chronic obstructive 10.2 TLR4 TLR2 MMP9 IL13 CRP CCL2
279 crohn's disease 10.2 TLR4 TLR2 IL2 IFNG CRP CCL2
280 trypanosomiasis 10.2 TLR6 TLR4 TLR2 IL2 IFNG CCL2
281 chagas disease 10.2 TLR6 TLR4 TLR2 IL2 IFNG CCL2
282 relapsing-remitting multiple sclerosis 10.2 TLR4 MMP9 IL2 IFNG CD40LG CCL2
283 trichomoniasis 10.2
284 visceral leishmaniasis 10.2 TLR4 TLR2 IL2 IL13 IFNG CRP
285 muscular disease 10.2 TLR4 MMP9 IL2 CRP CD40LG CCL2
286 agammaglobulinemia 10.2
287 severe combined immunodeficiency 10.2
288 parasitic helminthiasis infectious disease 10.2 TLR4 TLR2 IL2 IL13 IFNG CD40LG
289 autosomal dominant polycystic kidney disease 10.2 LCN2 CXCL12 CDH1 CCL2
290 scrub typhus 10.2 TLR4 TLR2 LCN2 IFNG CRP CD40LG
291 lymphoma, mucosa-associated lymphoid type 10.2 TLR4 TLR2 TLR1 HSPD1 CD40LG
292 pre-eclampsia 10.2 TLR4 MMP9 MMP2 CRP CD40LG
293 epidemic typhus 10.2 TLR4 TLR2 HSPD1 CRP CD40LG
294 cutaneous leishmaniasis 10.2 TLR4 TLR2 IL2 IL13 IFNG CCL2
295 toxoplasmosis 10.2 TLR4 TLR2 TLR1 IFNG HLA-DQA1 CD40LG
296 gliosarcoma 10.2 MMP9 MMP2 IL2 IFNG CTSB
297 uveitis 10.2 IL2 IFNG HSPD1 CCL2
298 ovarian cyst 10.2
299 dermatitis 10.2 TLR4 TLR2 IL2 IL13 IFNG CHI3L1
300 reactive arthritis 10.2 TLR4 TLR2 IFNG HSPD1 CRP
301 kawasaki disease 10.2 MMP9 HSPD1 CRP CD40LG CCL2
302 rectal disease 10.2 TLR6 TLR4 TLR2 TLR1 IL2 CRP
303 mixed connective tissue disease 10.2 IFNG HSPD1 HLA-DQA1 CD40LG
304 extrinsic cardiomyopathy 10.2 TLR4 TLR2 TLR1 IL2 CRP CD40LG
305 endocarditis 10.2 TLR6 TLR2 IFNG HSPD1 CRP
306 macular degeneration, age-related, 1 10.2 TLR4 TLR2 MMP9 MMP2 CRP CCL2
307 atherosclerosis susceptibility 10.2 TLR4 MMP9 HSPD1 CRP CCL2
308 sleep apnea 10.2 CRP CHI3L1 CCL2
309 bacteriuria 10.2 TLR4 TLR2 TLR1 TIRAP CRP CD40LG
310 measles 10.2 TLR4 TLR2 IL2 IFNG HLA-DQA1 CD40LG
311 leukorrhea 10.2
312 filariasis 10.1 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
313 combined t cell and b cell immunodeficiency 10.1
314 gingival overgrowth 10.1 MMP2 IL2 CTSB
315 peripheral nervous system disease 10.1 TLR4 TLR2 IL2 IFNG CRP CD40LG
316 actinomycosis 10.1
317 irritable bowel syndrome 10.1
318 ovarian epithelial cancer 10.1
319 splenic disease 10.1 TLR4 TLR2 IL2 IL13 IFNG CRP
320 nose disease 10.1 TLR4 TLR2 IL2 IL13 IFNG CRP
321 upper respiratory tract disease 10.1 TLR4 TLR2 IL2 IL13 IFNG CRP
322 vasculitis 10.1 LCN2 HSPD1 CRP CD40LG CCL2
323 mycobacterium tuberculosis 1 10.1 TLR4 TLR2 TLR1 IFNG HSPD1 CRP
324 parametritis 10.1
325 vaginitis 10.1
326 vulvovaginitis 10.1
327 osteoporosis 10.1 TLR4 MMP9 IL2 IFNG CRP CD40LG
328 viral hepatitis 10.1 TLR4 TLR2 IL2 IFNG HLA-DQA1 CRP
329 chediak-higashi syndrome 10.1
330 hypoglycemia 10.1
331 interstitial lung disease 10.0 MMP9 IL13 IFNG CXCL12 CRP CD40LG
332 coccidiosis 10.0 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
333 sarcoidosis 1 10.0 IL2 IL13 IFNG CRP CHI3L1 CD40LG
334 gastric adenocarcinoma 10.0 MMP9 MMP2 IFNG CXCL12 CRP CDH1
335 herpes simplex 10.0
336 47,xyy 10.0
337 lyme disease 10.0 TLR6 TLR2 TLR1 MMP9 HSPD1 CRP
338 aortic disease 10.0 MMP9 MMP2 CRP
339 autoimmune disease of central nervous system 10.0 TLR4 TLR2 TLR1 IL2 IL13 IFNG
340 viral infectious disease 10.0 TLR4 TLR2 TLR1 IL2 IL13 IFNG
341 psoriatic arthritis 10.0 TLR4 TLR2 IL2 IL13 IFNG CRP
342 leptospirosis 10.0 TLR2 TLR1 LCN2 IL2 IFNG CRP
343 pancreatic adenocarcinoma 10.0 MMP9 MMP2 IL2 CXCL12 CTSB CDH1
344 bone disease 10.0 MMP9 CXCL12 CHI3L1 CCL2
345 testicular disease 10.0 TLR4 TLR2 TLR1 IL2 IFNG HSPD1
346 thrombocytopenia 10.0 TLR4 TLR2 IL2 IFNG CXCL12 CRP
347 primary systemic mycosis 9.9 TLR4 TLR2 IL2 IFNG HSPD1 CRP
348 lymph node disease 9.9 TLR4 TLR2 IL2 IFNG HSPD1 CRP
349 renal cell carcinoma, nonpapillary 9.9 MMP9 MMP2 IL2 IL13 IFNG CDH1
350 endometrial cancer 9.9
351 human immunodeficiency virus type 1 9.9
352 tuberculous salpingitis 9.9
353 acute gonococcal cervicitis 9.9
354 leiomyoma 9.9
355 chronic gonococcal salpingitis 9.9
356 fallopian tube carcinoma 9.9
357 thrombophlebitis 9.9
358 myofibroma 9.9
359 ureteral obstruction 9.9
360 acute endometritis 9.9
361 genital herpes 9.9
362 cervix uteri carcinoma in situ 9.9
363 cervical intraepithelial neoplasia 9.9
364 haemophilus influenzae 9.9
365 back pain 9.9
366 autoimmune disease of musculoskeletal system 9.9 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
367 leukocyte adhesion deficiency, type i 9.9
368 leukemia, chronic lymphocytic 9.9
369 digeorge syndrome 9.9
370 anemia, autoimmune hemolytic 9.9
371 ataxia-telangiectasia 9.9
372 methane production 9.9
373 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.9
374 ataxia and polyneuropathy, adult-onset 9.9
375 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 9.9
376 autoimmune lymphoproliferative syndrome 9.9
377 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive 9.9
378 immunodeficiency 25 9.9
379 alacrima, achalasia, and mental retardation syndrome 9.9
380 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 9.9
381 hemophagocytic lymphohistiocytosis 9.9
382 immunoglobulin alpha deficiency 9.9
383 scoliosis 9.9
384 mastoiditis 9.9
385 lymphoproliferative syndrome 9.9
386 hyper ige syndrome 9.9
387 lymphocytic leukemia 9.9
388 dysgammaglobulinemia 9.9
389 telangiectasis 9.9
390 guillain-barre syndrome 9.9
391 polyneuropathy 9.9
392 thrombocytopenia due to platelet alloimmunization 9.9
393 neuroendocrine tumor 9.9
394 ectodermal dysplasia 9.9
395 pustulosis of palm and sole 9.9
396 poliomyelitis 9.9
397 chronic inflammatory demyelinating polyradiculoneuropathy 9.9
398 demyelinating polyneuropathy 9.9
399 chronic salpingitis 9.9
400 adenosine deaminase deficiency 9.9
401 hemolytic anemia 9.9
402 paraplegia 9.9
403 lymphopenia 9.9
404 psoriasis 9.9
405 albinism 9.9
406 atypical mycobacteriosis, familial 9.9
407 glioma 9.9
408 multifocal motor neuropathy 9.9
409 spinal cord injury 9.9
410 glial tumor 9.9
411 leishmaniasis 9.9 TLR4 TLR2 IL2 IL13 IFNG HLA-DQA1
412 arteriosclerosis 9.9 TLR4 MMP9 IFNG HSPD1 CXCL12 CRP
413 bronchiolitis 9.9 TLR6 TLR4 TLR2 TLR1 IL13 IFNG
414 opportunistic mycosis 9.9 TLR6 TLR4 TLR2 TLR1 IL2 IL13
415 esophageal cancer 9.9 TLR4 MMP9 MMP2 IL2 CXCL12 CRP
416 dermatitis, atopic 9.9 TLR6 TLR4 TLR2 TLR1 IL2 IL13
417 commensal bacterial infectious disease 9.8 TLR4 TLR2 TLR1 IL2 IFNG HSPD1
418 idiopathic interstitial pneumonia 9.8 IL13 IFNG CCL2
419 primary biliary cirrhosis 9.8 TLR4 IL2 IFNG HSPD1 HLA-DQA1 CD40LG
420 bone inflammation disease 9.8 TLR6 TLR4 TLR2 TLR1 MMP9 IL2
421 diabetes mellitus, noninsulin-dependent 9.8 TLR6 TLR4 TLR2 TLR1 MMP9 LCN2
422 arthritis 9.8 TLR4 TLR2 MMP9 IL13 IFNG HLA-DQA1
423 meralgia paraesthetica, familial 9.8
424 pelvic organ prolapse 9.8
425 ureterocele 9.8
426 renal hypodysplasia/aplasia 1 9.8
427 uterus bicornis bicollis with partial vaginal septum and unilateral hematocolpos with ipsilateral renal agenesis 9.8
428 lipoid congenital adrenal hyperplasia 9.8
429 insulin-like growth factor i 9.8
430 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 9.8
431 body mass index quantitative trait locus 9 9.8
432 body mass index quantitative trait locus 8 9.8
433 body mass index quantitative trait locus 4 9.8
434 body mass index quantitative trait locus 10 9.8
435 body mass index quantitative trait locus 7 9.8
436 diabetes mellitus, ketosis-prone 9.8
437 major affective disorder 8 9.8
438 body mass index quantitative trait locus 12 9.8
439 major affective disorder 9 9.8
440 body mass index quantitative trait locus 14 9.8
441 body mass index quantitative trait locus 18 9.8
442 body mass index quantitative trait locus 19 9.8
443 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
444 body mass index quantitative trait locus 20 9.8
445 small cell carcinoma 9.8
446 thrombosis 9.8
447 paragonimiasis 9.8
448 salpingo-oophoritis 9.8
449 hydronephrosis 9.8
450 endometriosis of ovary 9.8
451 portal vein thrombosis 9.8
452 neutropenia 9.8
453 pancytopenia 9.8
454 chancroid 9.8
455 interstitial cystitis 9.8
456 mental depression 9.8
457 pneumothorax 9.8
458 heart septal defect 9.8
459 atrial heart septal defect 9.8
460 hepatitis b 9.8
461 constipation 9.8
462 nocardiosis 9.8
463 myoma 9.8
464 proctitis 9.8
465 chronic granulomatous disease 9.8
466 bipolar disorder 9.8
467 sleep disorder 9.8
468 lice infestation 9.8
469 adenoma 9.8
470 diverticulitis 9.8
471 peptic ulcer disease 9.8
472 peptic ulcer perforation 9.8
473 scabies 9.8
474 intestinal obstruction 9.8
475 paralytic ileus 9.8
476 in situ carcinoma 9.8
477 uterine inversion 9.8
478 hypereosinophilic syndrome 9.8
479 cytokine deficiency 9.8
480 double uterus-hemivagina-renal agenesis 9.8
481 infectious myocarditis 9.8
482 ovarian remnant syndrome 9.8
483 splenomegaly 9.8
484 streptococcal group a invasive disease 9.8
485 depression 9.8
486 longitudinal vaginal septum 9.8
487 transient pseudohypoaldosteronism 9.8
488 streptococcal toxic-shock syndrome 9.8
489 precursor t-cell acute lymphoblastic leukemia 9.8
490 periodontitis 9.8 TLR4 TLR2 MMP9 MMP2 IFNG HSPD1
491 immune system disease 9.8 TLR6 TLR4 TLR2 TLR1 IL2 IL13
492 parasitic protozoa infectious disease 9.8 TLR6 TLR4 TLR2 TLR1 IL2 IL13
493 bronchial disease 9.8 TLR6 TLR4 TLR2 TLR1 IL2 IL13
494 glioblastoma multiforme 9.7 MMP9 MMP2 IL2 IL13 IFNG CXCL12
495 celiac disease 1 9.7 TLR6 TLR4 TLR2 TLR1 IL2 IL13
496 leprosy 3 9.6 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
497 vascular disease 9.6 TLR4 MMP9 IL2 IFNG HSPD1 CXCL12
498 connective tissue disease 9.6 TLR4 TLR2 IL2 IFNG HSPD1 HLA-DQA1
499 dilated cardiomyopathy 9.6 TLR4 MMP9 MMP2 IL2 IFNG HSPD1
500 eye disease 9.5 TLR4 TLR2 MMP9 MMP2 IL2 IL13
501 primary bacterial infectious disease 9.4 TLR6 TLR4 TLR2 TLR1 IL2 IL13
502 behcet syndrome 9.4 TLR6 TLR4 TLR2 TLR1 IL2 IL13
503 pulmonary fibrosis, idiopathic 9.4 TLR4 TLR2 MMP9 MMP2 IL13 IFNG
504 hypertension, essential 9.4 TLR6 TLR4 TLR2 TLR1 MMP9 MMP2
505 diabetes mellitus 9.3 TLR4 TLR2 MMP9 LCN2 IL2 IFNG
506 multiple sclerosis 9.3 TLR4 TLR2 MMP9 IL2 IL13 IFNG
507 diabetes mellitus, insulin-dependent 9.2 TLR6 TLR4 TLR2 TLR1 IL2 IL13
508 asthma 9.1 TLR6 TLR4 TLR2 TLR1 MMP9 MMP2
509 systemic lupus erythematosus 9.0 TLR4 TLR2 MMP9 LCN2 IL2 IL13
510 malaria 8.9 TLR6 TLR4 TLR2 TLR1 TIRAP MMP9
511 rheumatoid arthritis 8.7 TLR4 TLR2 MMP9 MMP2 IL2 IL13
512 inflammatory bowel disease 8.3 TLR6 TLR4 TLR2 TLR1 MMP9 MMP2

Comorbidity relations with Pelvic Inflammatory Disease via Phenotypic Disease Network (PDN): (showing 1, show less)


Acute Cystitis

Graphical network of the top 20 diseases related to Pelvic Inflammatory Disease:



Diseases related to Pelvic Inflammatory Disease

Symptoms & Phenotypes for Pelvic Inflammatory Disease

UMLS symptoms related to Pelvic Inflammatory Disease:


fever, pruritus, pelvic pain

GenomeRNAi Phenotypes related to Pelvic Inflammatory Disease according to GeneCards Suite gene sharing:

26 (showing 1, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCL2 CDH1 HLA-DQA1 HSPD1 LCN2 MMP2

MGI Mouse Phenotypes related to Pelvic Inflammatory Disease:

45 (showing 10, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.3 CCL2 CD40LG CDH1 CHI3L1 CRP CTSB
2 hematopoietic system MP:0005397 10.28 CD40LG CHI3L1 CXCL12 HLA-DQA1 IFNG IL13
3 cellular MP:0005384 10.27 CD40LG CDH1 CHI3L1 CTSB CXCL12 HSPD1
4 cardiovascular system MP:0005385 10.26 CD40LG CDH1 CRP CXCL12 IFNG IL2
5 homeostasis/metabolism MP:0005376 10.18 CD40LG CDH1 CRP CTSB IFNG IL13
6 mortality/aging MP:0010768 10.1 CD40LG CDH1 CTSB CXCL12 HSPD1 IFNG
7 digestive/alimentary MP:0005381 10.03 CDH1 CTSB IFNG IL13 IL2 MMP9
8 muscle MP:0005369 9.76 CXCL12 HSPD1 IFNG IL13 MMP2 MMP9
9 neoplasm MP:0002006 9.56 CDH1 CTSB IFNG IL2 MMP2 MMP9
10 reproductive system MP:0005389 9.36 CD40LG CDH1 CXCL12 HSPD1 IFNG IL13

Drugs & Therapeutics for Pelvic Inflammatory Disease

Drugs for Pelvic Inflammatory Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 81, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
2
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
7
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
8
Gemifloxacin Approved, Investigational Phase 4 175463-14-6 5464436 9571107
9
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
10
Metronidazole Approved Phase 4 443-48-1 4173
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Azithromycin Approved Phase 4 83905-01-5 55185 447043
13
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
14 Renal Agents Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16 Norgestimate, ethinyl estradiol drug combination Phase 4
17 Estradiol 17 beta-cypionate Phase 4
18 Topoisomerase Inhibitors Phase 4
19 Contraceptives, Oral, Combined Phase 4
20 Anti-Infective Agents, Urinary Phase 4
21 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
22 Contraceptives, Oral Phase 4
23 Estradiol 3-benzoate Phase 4
24 Alkylating Agents Phase 4
25 Gentamicins Phase 4
26 Acidophilus Phase 4
27 Antibiotics, Antitubercular Phase 4
28 Antitubercular Agents Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anti-Infective Agents Phase 4
31 Antiparasitic Agents Phase 4
32 Anti-Bacterial Agents Phase 4
33 Antiprotozoal Agents Phase 4
34 Antimalarials Phase 4
35 Carboxymethylcellulose Sodium Phase 4
36
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
37
Copper Approved, Investigational Phase 3 7440-50-8 27099
38
Cefixime Approved, Investigational Phase 3 79350-37-1 54362 5362065
39 Contraceptive Agents Phase 3
40 Hormones Phase 3
41
Ticarcillin Approved, Investigational, Vet_approved Phase 2 34787-01-4 36921
42
Clavulanate Approved, Vet_approved Phase 2 58001-44-8 5280980
43
Ertapenem Approved, Investigational Phase 2 153832-46-3 150610
44
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
45 Kava Approved, Investigational, Nutraceutical Phase 2 9000-38-8
46 beta-Lactamase Inhibitors Phase 2
47 diuretics Phase 2
48 Pharmaceutical Solutions Phase 1
49
Curcumin Approved, Experimental, Investigational 458-37-7 969516
50
Cefuroxime Approved 55268-75-2 5361202 5479529
51
Clarithromycin Approved 81103-11-9 84029
52
Telithromycin Approved 191114-48-4 5462516 70789201
53
Amoxicillin Approved, Vet_approved 26787-78-0 33613
54
Levonorgestrel Approved, Investigational 797-63-7, 17489-40-6 13109
55
Aspartic acid Approved, Nutraceutical 56-84-8 5960
56
Deslorelin Investigational, Vet_approved 57773-65-6
57 Anti-Inflammatory Agents, Non-Steroidal
58 Analgesics, Non-Narcotic
59 Antirheumatic Agents
60 cefuroxime axetil
61 Cytochrome P-450 CYP3A Inhibitors
62 Liver Extracts
63 Amoxicillin-Potassium Clavulanate Combination
64 Fluoroquinolones
65 Triptorelin Pamoate
66 Chorionic Gonadotropin
67 Gonadotropins, Pituitary
68 Anti-Retroviral Agents
69 N-Methylaspartate
70 Immunologic Factors
71 Complement System Proteins
72 Analgesics
73 Micronutrients
74 Trace Elements
75 Nutrients
76 Protective Agents
77 Antioxidants
78 Omega 3 Fatty Acid
79 Vitamins
80 Anesthetics
81
L-Alanine Nutraceutical 56-41-7 5950

Interventional clinical trials:

(showing 69, show less)
# Name Status NCT ID Phase Drugs
1 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
2 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
3 Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials Completed NCT01799356 Phase 4 Moxifloxacin;Ofloxacin;Metronidazole
4 Phase 4 Study of Azitromicin in the Treatment of PID Completed NCT01241110 Phase 4 Ofloxacin group A, Azitromycin group B;azitromycin
5 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
6 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
7 Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea Completed NCT00926796 Phase 4 Azithromycin;Gentamicin;Gemifloxacin
8 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
9 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
10 A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome):a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study Not yet recruiting NCT04031664 Phase 4 Qianjin Capsule of Gynaecology
11 A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation):a Randomized, Double Blind, Parallel Control of Positive Drugs,Multi-center Clinical Study Not yet recruiting NCT04035785 Phase 4 Kangfu Anti-inflammatory Suppository
12 Randomized, Open-label, Multicenter Study of Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Not yet recruiting NCT03532464 Phase 4 azithromycin;doxycycline
13 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
14 Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID) Completed NCT00683865 Phase 3 Ofloxacin;Avelox (Moxifloxacin, BAY12-8039)
15 A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 Days in Subjects With an Uncomplicated Pelvic Inflammatory Disease (PID). Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study) Completed NCT00453349 Phase 3 Moxifloxacin (Avelox, BAY12-8039);Levofloxacin & Metronidazole
16 A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Pelvic Inflammatory Disease (PID) Requiring Initial Intravenous Therapy Completed NCT00871494 Phase 3 Azithromycin
17 A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone Completed NCT01473836 Phase 3 Metronidazole;Ceftriaxone sodium
18 Home Screening for Chlamydia Surveillance Completed NCT00177437 Phase 3
19 A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept™, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability Active, not recruiting NCT03633799 Phase 3 VeraCept
20 A Randomized Trial to Evaluate the Need for Empiric Therapy for Mucopurulent Cervicitis of Unknown Etiology Terminated NCT01072136 Phase 3 Azithromycin;Cefixime
21 Clinical Promotion Research of Complex Treatment With TCM to Diagnosis and Treatment on Different Syndrome Types of Pelvic Inflammatory Disease Sequelae Unknown status NCT02972151 Phase 2 Comprehensive treatment of TCM
22 The Importance of Anti-anaerobic Therapy for Acute PID Completed NCT01160640 Phase 2 Ceftriaxone;Doxycycline;Metronidazole;Placebo Oral Capsule
23 A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients Completed NCT00092170 Phase 2 MK0826, ertapenem sodium;Comparator: Ticarcillin/Clavulanate
24 MANAGEMENT OF THE PATIENT WITH ACUTE ABDOMEN SUBMITTED TO URGENT ABDOMINAL SURGERY: a Pilot Randomized Multicentre Study Completed NCT01911702 Phase 2
25 The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation Recruiting NCT03251560 Phase 2 Fuke Qianjin capsule;Placebo oral capsule
26 Intrauterine Infusion of Autologous Platelet-Rich Plasma (PRP) in Women With Thin Endometrium Undergoing Embryo-transfer. Recruiting NCT03067623 Phase 2 PRP
27 Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers Completed NCT03054402 Phase 1 BAY1834845;Placebo
28 Curcumin Supplementation for Gynecological Diseases Including Pelvic Inflammatory Disease Endometritis, Endometriosis: A Pilot Study Unknown status NCT03016039
29 Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users Unknown status NCT03261804
30 Rate of Pelvic Inflammatory Disease and Tubo-ovarian Abscess at SMH Completed NCT00783419
31 Improving Primary Care Follow-up for Adolescents With PID: A Randomized Controlled Trial Using Text Message Reminders Completed NCT01299259
32 To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy Completed NCT01842100 Universal antibiotic prophylaxis
33 Characterization of Novel Organisms in the Genital Tract of Women With PID and Determination of Their Association With Endometritis. Completed NCT01236131
34 Drug Use Investigation Of Azithromycin Iv Completed NCT01671280 Azithromycin IV
35 Immunopathogenesis of Chlamydia Trachomatis Infection Completed NCT00607659
36 Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease Completed NCT00115388
37 Technology Enhanced Community Health Nursing (TECH-N) to Prevent Recurrent Sexually Transmitted Infections After Pelvic Inflammatory Disease Completed NCT01640379
38 Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success Completed NCT01793584
39 Recurrent Bacterial Vaginosis (RBV): Efficiency of Metronidazole in Comparison to Metronidazole and Intravaginal Acidifying Gel: A Randomized Investigator-blinded Controlled Trial Completed NCT00545181 Vaginal acidifying gel (RepHresh);Metronidazole control
40 Zithromac Iv Special Investigation For Legionella Infection. Completed NCT01784770 Azithromycin IV
41 Longitudinal Study of Vaginal Flora Completed NCT00340275
42 DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women Completed NCT01874158
43 Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population Completed NCT01434173 Moxifloxacin (Avelox, BAY12-8039);Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
44 The Measurement of Endometrial Volume and Sub-endometrial Vascularity to Replace the Traditional Endometrial Thickness as Predictors of In-vitro Fertilization Success Completed NCT02381821 GnRH agonist
45 Antigen-specific Cell Mediated Immune Response to Chlamydia Trachomatis Completed NCT00970749
46 Quick Start Insertion of Mirena and ParaGard Intrauterine Contraceptive Devices Completed NCT01730911
47 HIV Risk Reduction for Women Reporting Intimate Partner Violence Completed NCT01695694
48 Evaluation of an Inpatient Sexual Risk Behavior Assessment Program Completed NCT03502226
49 Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women. - A Randomised Control Trial Completed NCT00283127
50 Comparison of Two IUDs Among Cape Town HIV-positive Women: A Randomized Controlled Trial Assessing Safety of Registered Products in South Africa Completed NCT01721798
51 Complement Diagnosis of Acute Appendicitis Completed NCT03450642
52 The Effect of the Levonorgestrel-Releasing Intrauterine System and the Copper-Intrauterine Device (TCu 380A) on Subendometrial Microvascularization and Uterine Artery Blood Flow. Completed NCT00489463
53 Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women Completed NCT02272231
54 Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract Completed NCT00299663
55 Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase of Infertile Women With Natural Cycles Completed NCT01533350
56 Diagnostic Yield of Narrow Band Imaging (NBI) and Standard Visible White Light Laparoscopy for the Detection of Endometriosis Completed NCT01464775
57 Prospective Data Collection of Patients With Pelvic Inflammatory Disease Recruiting NCT02567812
58 Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID Recruiting NCT03828994
59 Prevention of Diseases Induced by Chlamydia Trachomatis Recruiting NCT02904811
60 Efficacy of Resistive Capacitive Monopolar Radiofrequency in the Physiotherapeutic Treatment of Chronic Pelvic Pain: Randomized Clinical Trial. Recruiting NCT03797911
61 STD Testing in Outpatient Practices-The STOP STDs Study Recruiting NCT03246815
62 European Active Surveillance Study of LCS12 Recruiting NCT02146950
63 Enriched Environments: a Multi-level Integrative Medicine Intervention for Endometriosis Recruiting NCT04179149
64 Chlamydia Tracomatis and Other Lower Genital Tract Infections Among Women With Unexplained Early Miscarriage Recruiting NCT04152278
65 Effect of an Anti-inflammatory Diet on the Nutritional Status and Cytokine Expression of Patients With Locally Advanced Cervical Cancer: A Randomized Clinical Trial Recruiting NCT03994055
66 Cross Sectional Study of Iatrogenic Urinary Tract Injuries During Obstetric and Gynecological Operations in Assiut University Women Health Hospital Not yet recruiting NCT04162782
67 Comparative Study of Hysteroscopic Versus Laparoscopic Tubal Occlusion in Cases of Communicating Hydrosalpinx and Planning for IVF Not yet recruiting NCT04037813
68 Improving the Detection of STIs in the Pediatric Emergency Department: A Pragmatic Trial Not yet recruiting NCT03715335
69 A Randomized, Controlled Trial of Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis Terminated NCT00997516

Search NIH Clinical Center for Pelvic Inflammatory Disease

Cochrane evidence based reviews: pelvic inflammatory disease

Genetic Tests for Pelvic Inflammatory Disease

Anatomical Context for Pelvic Inflammatory Disease

MalaCards organs/tissues related to Pelvic Inflammatory Disease:

40
Testes, Uterus, Ovary, T Cells, Lung, Heart, Liver

Publications for Pelvic Inflammatory Disease

Articles related to Pelvic Inflammatory Disease:

(showing 3882, show less)
# Title Authors PMID Year
1
Incidence and sequelae of acute pelvic inflammatory disease among active component females, U.S. Armed Forces, 1996-2016. 61 42
31066569 2018
2
Mycoplasma genitalium infection. 42
31628115 2019
3
Impact of endometritis on post-partum ovarian cyclicity in dairy cows. 42
31113569 2019
4
Chlamydia pneumoniae as a respiratory pathogen. 54 61
11861211 2002
5
Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic inflammatory disease. 54 61
9498452 1998
6
Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin. 54 61
18475331 1993
7
Differential human serologic response to two 60,000 molecular weight Chlamydia trachomatis antigens. 54 61
2205652 1990
8
Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis. 61
32037193 2020
9
Misconceptions and Beliefs Regarding the Use of Intrauterine Devices for Nulliparous Women Among Chinese Health Care Providers. 61
31648037 2020
10
Increased prevalence of endocervical Mycoplasma and Ureaplasma colonization in infertile women with tubal factor. 61
32031768 2020
11
[Recurrent Urogynecological Infections]. 61
32019451 2020
12
Can the Need for Invasive Intervention in Tubo-ovarian Abscess Be Predicted? The Implication of C-reactive Protein Measurements. 61
31479751 2020
13
Mycoplasma genitalium prevalence in Welsh sexual health patients: Low antimicrobial resistance markers and no association of symptoms to bacterial load. 61
31756372 2020
14
Congenital adrenal hyperplasia presenting as pelvic inflammatory disease in a phenotypic male: A case report. 61
31914016 2020
15
Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma. 61
31983516 2020
16
Analysis of low sexual desire in Chinese women: a national population-based epidemiological survey in mainland China. 61
31945308 2020
17
Risk factors for recurrent Pelvic Inflammatory Disease. 61
31734623 2020
18
Mycoplasma genitalium: A Review. 61
31329090 2020
19
A profile of the cobas® TV/ MG test for the detection of Trichomonas vaginalis and Mycoplasma genitalium. 61
31917618 2020
20
Efficacy of Antibiotic Prophylaxis for Hysteroscopy: A Meta-Analysis of Randomized Trials. 61
31302246 2020
21
Prevalence and incidence of Mycoplasma genitalium in a cohort of HIV-infected and HIV-uninfected pregnant women in Cape Town, South Africa. 61
31932358 2020
22
[Borderline ovarian tumours: CNGOF Guidelines for clinical practice - Epidemiological aspects and risk factors]. 61
32004787 2020
23
Complications after hysterosalpingography with oil- or water-based contrast: results of a nationwide survey. 61
31976383 2020
24
Communication and management of incidental pathology in 1,214 consecutive appendicectomies; a cohort study. 61
31683040 2019
25
Dissemination of Chlamydia from the reproductive tract to the gastro-intestinal tract occurs in stages and relies on Chlamydia transport by host cells. 61
31790512 2019
26
Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients. 61
31882737 2019
27
Chlamydia trachomatis Whole-Proteome Microarray Analysis of The Netherlands Chlamydia Cohort Study. 61
31888186 2019
28
Novel bacterial vaginosis-associated organisms mediate the relationship between vaginal douching and pelvic inflammatory disease. 61
31810995 2019
29
Cross-sectional imaging of acute gynaecologic disorders: CT and MRI findings with differential diagnosis-part II: uterine emergencies and pelvic inflammatory disease. 61
31858287 2019
30
Streptococcal Toxic Shock Syndrome After Insertion of a Levonorgestrel Intrauterine Device. 61
30981616 2019
31
Unindicated hysterectomies in India: the aftermath. 61
31852688 2019
32
Trichomonas vaginalis, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease. 61
31719170 2019
33
Heterotopic Pregnancy: A Challenge in Early Diagnosis. 61
31735941 2019
34
Status of vaccine research and development of vaccines for Chlamydia trachomatis infection. 61
28111145 2019
35
Douching, Talc Use, and Risk for Ovarian Cancer and Conditions Related to Genital Tract Inflammation. 61
31455671 2019
36
Comparison of the Analgesic and Anti-Inflammatory Effects of Xiaoyuningkun Decoction with Cynanchum Paniculatum and Fukeqianjin in a Mouse Model of Pelvic Inflammatory Disease. 61
31784502 2019
37
[Systemic evaluation and Meta-analysis of efficacy and safety of Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory disease]. 61
31872607 2019
38
[Mechanisms of Fuke Qianjin Capsules in treatment of pelvic inflammatory disease based on GC-MS metabolomics]. 61
31872604 2019
39
Pelvic inflammatory disease and risk of cancer: A nationwide cohort study. 61
31765001 2019
40
Pelvic inflammatory disease: An unusual cause of acute intestinal obstruction. 61
30982548 2019
41
Female Nonobstetric Genitourinary Emergencies. 61
31563207 2019
42
National Institute of Allergy and Infectious Diseases workshop report: "Chlamydia vaccines: The way forward". 61
29097007 2019
43
High rates of treatment failure for Mycoplasma genitalium among men and women attending a sexual health clinic. 61
31722934 2019
44
Biological feasibility and importance of a gonorrhea vaccine for global public health. 61
29680200 2019
45
Peritoneal adhesions are an independent risk factor for peri- and post-partum infectious morbidity. 61
31442735 2019
46
Risk of Ectopic Pregnancy and Tubal Infertility Following Gonorrhea and Chlamydia Infections. 61
30778532 2019
47
Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease, Ectopic Pregnancy, and Female Infertility: A Retrospective Cohort Study Among Primary Care Patients. 61
31504315 2019
48
[Chlamydia trachomatis infection's eradication : a daily goal]. 61
31643153 2019
49
Acute pelvic inflammatory disease as a rare cause of acute small bowel obstruction. 61
29560794 2019
50
Partner Notification, Treatment, and Subsequent Condom Use After Pelvic Inflammatory Disease: Implications for Dyadic Intervention With Urban Youth. 61
31165630 2019
51
Infections caused by Chlamydia trachomatis (including lymphogranuloma venereum) and Mycoplasma genitalium. 61
30878312 2019
52
Causes and Prevalence of Factors Causing Infertility in a Public Health Facility. 61
32038077 2019
53
Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention. 61
31524362 2019
54
Mycoplasma genitalium, a stealth female reproductive tract. 61
31522281 2019
55
Erratum to: Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease, Ectopic Pregnancy, and Female Infertility: A Retrospective Cohort Study Among Primary Care Patients. 61
31535123 2019
56
Polycystic ovarian morphology is associated with primary dysmenorrhea in young Korean women. 61
31538076 2019
57
An update on prevalence, diagnosis, treatment and emerging issues of genital mycoplasma infection in Indian women: A narrative review. 61
31389367 2019
58
An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. 61
31369673 2019
59
Current usage of qualitative research in female pelvic pain: a systematic review. 61
31201537 2019
60
The Influencing Factors of Venous Intravasation During Transvaginal Four-dimensional Hysterosalpingo-contrast Sonography With SonoVue. 61
31201020 2019
61
Ultrasonographic and multimodal imaging of pediatric genital female diseases. 61
30778893 2019
62
Ovarian abscess caused by Salmonella enterica serovar Typhi: a case report. 61
31551082 2019
63
Association Between Forced Sexual Initiation and Health Outcomes Among US Women. 61
31524926 2019
64
No. 385-Indications for Pelvic Examination. 61
31331610 2019
65
Xanthogranulomatous Salpingitis. 61
31433377 2019
66
Hydrosalpinx - Salpingostomy, salpingectomy or tubal occlusion. 61
30824209 2019
67
Intravasation Affects the Diagnostic Image Quality of Transvaginal 4-Dimensional Hysterosalpingo-Contrast Sonography With SonoVue. 61
30597629 2019
68
Please Be Careful with Me: Discrepancies between Adolescent Expectations and Clinician Perspectives on the Management of Pelvic Inflammatory Disease. 61
30974212 2019
69
Efficacy of a Technology-Enhanced Community Health Nursing Intervention vs Standard of Care for Female Adolescents and Young Adults With Pelvic Inflammatory Disease: A Randomized Clinical Trial. 61
31390037 2019
70
Fitz-Hugh-Curtis syndrome resulting in nutmeg liver on computed tomography. 61
31193761 2019
71
The Dangers of Hymenotomy for Imperforate Hymen: A Case of Iatrogenic Pelvic Inflammatory Disease with Pyosalpinx. 61
30974214 2019
72
Reliability of administrative data to identify sexually transmitted infections for population health: a systematic review. 61
31399425 2019
73
Effect of Time of Day of Infection on Chlamydia Infectivity and Pathogenesis. 61
31388084 2019
74
Role of general gynaecologists in the prevention of infertility. 61
30837119 2019
75
Factors associated with anorectal Chlamydia trachomatis or Neisseria gonorrhoeae test positivity in women: a systematic review and meta-analysis. 61
31097677 2019
76
Mycoplasma genitalium incidence, persistence, concordance between partners and progression: systematic review and meta-analysis. 61
31055469 2019
77
Potential for Point-of-Care Tests to Reduce Chlamydia-associated Burden in the United States: A Mathematical Modeling Analysis. 61
31504314 2019
78
Higher Prevalence of Endometrial Polyps in Patients with Fallopian Tube Obstruction: A Case-control Study. 61
30273685 2019
79
A case of obstructed hemivagina and ipsilateral renal anomaly syndrome complicated with pyometra: tips and tricks for laparoscopic hemihysterectomy. 61
31126713 2019
80
Estimated burden of Chlamydia trachomatis female infection and consequent severe pelvic inflammatory disease, Italy, 2005-2016. 61
31553313 2019
81
[Guideline of pelvic inflammatory disease (2019 revised edition)]. 61
31365954 2019
82
Therapeutic Impact of Initial Treatment for Chlamydia trachomatis Among Patients With Pelvic Inflammatory Disease: A Retrospective Cohort Study Using a National Inpatient Database in Japan. 61
30312389 2019
83
Self-Reported Infertility and Associated Pelvic Inflammatory Disease Among Women of Reproductive Age-National Health and Nutrition Examination Survey, United States, 2013-2016. 61
31194716 2019
84
Concurrency of splenomegaly and numerous enlarged mesenteric and retroperitoneal lymph nodes in a patient with pelvic inflammatory disease caused by Edwardsiella tarda: Mimicking lymphoma. 61
30887633 2019
85
Surgical Management and Prevention of Ovarian Remnant. 61
30414999 2019
86
Prevalence and Risk Factors of Trichomonas vaginalis Among Female Sexual Workers in Nairobi, Kenya. 61
31194717 2019
87
Management of gonorrhoea in a hospital network: are we following best practice? 61
31292064 2019
88
Evaluation of Positron Emission Tomography and Contrast-Enhanced Computed Tomography Scan in Nodal Staging of Early Operable Uterine Cancers. 61
31293295 2019
89
The predictive role of CA-125 in the management of tubo-ovarian abscess. A retrospective study. 61
31082739 2019
90
The human tubal lavage proteome reveals biological processes that may govern the pathology of hydrosalpinx. 61
31222072 2019
91
Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial. 61
30606817 2019
92
Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study. 61
30871933 2019
93
Laparoscopic Compared With Open Surgery for Severe Pelvic Inflammatory Disease and Tubo-Ovarian Abscess. 61
31135738 2019
94
Pelvic Inflammatory Disease in a Pediatric Emergency Department: Epidemiology and Treatment. 61
28441241 2019
95
Benefits of second-look laparoscopy in the management of pelvic inflammatory disease. 61
30910760 2019
96
[Effect of Fuyanshu Capsules combined with antibiotics on inflammatory factors in patients with pelvic inflammatory disease]. 61
31359734 2019
97
Protective effects of Asiatic acid against pelvic inflammatory disease in rats. 61
31086602 2019
98
Common Bacterial and Viral Infections: Review of Management in the Pregnant Patient. 61
30556401 2019
99
Comprehensive characterization and quantification of multiple components in Dan-Huang-Qu-Yu capsule using a multivariate data processing approach based on microwave-assisted extraction with UHPLC and Q Exactive quadrupole-orbitrap high-resolution mass spectrometry. 61
30942527 2019
100
Hysterosalpingographic findings in infertility - what has changed over the years? 61
31656469 2019
101
Tubo-ovarian abscess with sepsis in a nonagenarian woman: a case report and literature review. 61
31216992 2019
102
Selected Immunological Mediators and Cervical Microbial Signatures in Women with Chlamydia trachomatis Infection. 61
31164450 2019
103
[Follow-up and counselling after pelvic inflammatory disease: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 61
30878686 2019
104
Ultrasound of Pelvic Pain in the Nonpregnant Woman. 61
30928080 2019
105
Laparoscopic Compared With Open Surgery for Severe Pelvic Inflammatory Disease and Tubo-Ovarian Abscess. 61
31083118 2019
106
[Treatment of uncomplicated pelvic inflammatory disease: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 61
30878689 2019
107
[Diagnosis of pelvic inflammatory disease: Clinical, paraclinical, imaging and laparoscopy criteria. CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 61
30878687 2019
108
[Management of tubo-ovarian abscesses and complicated pelvic inflammatory disease: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 61
30880246 2019
109
The compatibility of six alkaloids in ermiao pill explored by a comparative pharmacokinetic and network pharmacological study. 61
30756408 2019
110
Suspected gonorrhea and chlamydia: Incidence and utilization of empiric antibiotics in a health system emergency department. 61
30119987 2019
111
Acute Pelvic Pain. 61
30940367 2019
112
[Pelvic Inflammatory Diseases: Updated Guidelines for Clinical Practice - Short version]. 61
30880245 2019
113
Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies. 61
30894687 2019
114
Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. 61
30753898 2019
115
Chlamydia trachomatis in women with pelvic inflammatory disease (PID): report from a tertiary center in eastern Nepal. 61
30755106 2019
116
Trends in diagnosis of pelvic inflammatory disease in an Australian sexual health clinic, 2002-16: before and after clinical audit feedback. 61
30940330 2019
117
Why a Pelvic Exam is Needed to Diagnose Cervicitis and Pelvic Inflammatory Disease. 61
30902176 2019
118
Pediatric pyosalpinx without sexually transmitted infection: A report of 3 cases. 61
30815048 2019
119
Actinomycotic Endometritis. 61
29369919 2019
120
Improving Women's Health and Combatting Sexually Transmitted Infections Through Expedited Partner Therapy. 61
30741802 2019
121
Abdominal Actinomycosis Mimicking Colon Cancer. 61
31060658 2019
122
[Pelvic inflammatory disease is a rare cause of acute abdomen in a child]. 61
30869072 2019
123
Discovery of anti-inflammatory terpenoids from Mallotus conspurcatus croizat. 61
30445108 2019
124
Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations. 61
29790947 2019
125
[Acute Pelvic pain in women-gynecological causes]. 61
30519765 2019
126
The first reported case of pelvic inflammatory disease caused by Actinobaculum massiliense. 61
30439470 2019
127
Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials. 61
30341232 2019
128
Clinical Features and Therapeutic Response in Women Meeting Criteria for Presumptive Treatment for Pelvic Inflammatory Disease Associated With Mycoplasma genitalium. 61
30640861 2019
129
Emergent genital infection by Leptotrichia trevisanii. 61
29980937 2019
130
A novel fluorescence method for activity assay and drug screening of T4 PNK by coupling rGO with ligase reaction. 61
30566137 2019
131
Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention. 61
30321529 2019
132
Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: There is no time like the present. 61
31015819 2019
133
A unique insight into the MiRNA profile during genital chlamydial infection. 61
30777008 2019
134
TLR3 deficiency exacerbates the loss of epithelial barrier function during genital tract Chlamydia muridarum infection. 61
30625140 2019
135
The Risk of Gynecologic and Urinary Tract Cancer with Pelvic Inflammatory Disease: A Population-Based Cohort Study. 61
30662522 2019
136
Use of Human Fallopian Tube Organ in Culture (FTOC) and Primary Fallopian Tube Epithelial Cells (FTEC) to Study the Biology of Neisseria gonorrhoeae Infection. 61